199 related articles for article (PubMed ID: 20024547)
1. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked.
von Lilienfeld-Toal M; Frank S; Leyendecker C; Feyler S; Jarmin S; Morgan R; Glasmacher A; Märten A; Schmidt-Wolf IG; Brossart P; Cook G
Cancer Immunol Immunother; 2010 Jun; 59(6):829-39. PubMed ID: 20024547
[TBL] [Abstract][Full Text] [Related]
2. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
3. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia.
Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M
Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181
[TBL] [Abstract][Full Text] [Related]
4. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
[TBL] [Abstract][Full Text] [Related]
5. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.
Crane CA; Han SJ; Barry JJ; Ahn BJ; Lanier LL; Parsa AT
Neuro Oncol; 2010 Jan; 12(1):7-13. PubMed ID: 20150362
[TBL] [Abstract][Full Text] [Related]
6. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.
Lundholm M; Schröder M; Nagaeva O; Baranov V; Widmark A; Mincheva-Nilsson L; Wikström P
PLoS One; 2014; 9(9):e108925. PubMed ID: 25268476
[TBL] [Abstract][Full Text] [Related]
7. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
Front Immunol; 2018; 9():926. PubMed ID: 29765374
[TBL] [Abstract][Full Text] [Related]
8. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
9. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
10. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
[TBL] [Abstract][Full Text] [Related]
11. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance.
Vulpis E; Loconte L; Peri A; Molfetta R; Caracciolo G; Masuelli L; Tomaipitinca L; Peruzzi G; Petillo S; Petrucci MT; Fazio F; Simonelli L; Fionda C; Soriani A; Cerboni C; Cippitelli M; Paolini R; Bernardini G; Palmieri G; Santoni A; Zingoni A
J Extracell Vesicles; 2022 Jan; 11(1):e12176. PubMed ID: 34973063
[TBL] [Abstract][Full Text] [Related]
12. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients.
Dulphy N; Berrou J; Campillo JA; Bagot M; Bensussan A; Toubert A
J Invest Dermatol; 2009 Feb; 129(2):359-64. PubMed ID: 18754036
[TBL] [Abstract][Full Text] [Related]
13. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
Cerboni C; Ardolino M; Santoni A; Zingoni A
Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
[TBL] [Abstract][Full Text] [Related]
14. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
15. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
Ge X; Li CR; Yang J; Wang GB
Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
[TBL] [Abstract][Full Text] [Related]
16. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
17. The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients.
Mou X; Zhou Y; Jiang P; Zhou T; Jiang Q; Xu C; Liu H; Zheng T; Yuan G; Zhang Y; Chen D; Mao C
Sci Rep; 2014 Aug; 4():6138. PubMed ID: 25138242
[TBL] [Abstract][Full Text] [Related]
18. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
19. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
20. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity.
Cao W; Xi X; Hao Z; Li W; Kong Y; Cui L; Ma C; Ba D; He W
J Biol Chem; 2007 Jun; 282(26):18922-8. PubMed ID: 17470428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
